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Abstract
Muscle potentially represents the most abundant source of autoantigens of the body and can be targeted by a variety of
severe autoimmune diseases. Yet, the mechanisms of immunological tolerance toward muscle autoantigens remain mostly
unknown. We investigated this issue in transgenic SM-Ova mice that express an ovalbumin (Ova) neo-autoantigen
specifically in skeletal muscle. We previously reported that antigen specific CD4
+ T cell are immunologically ignorant to
endogenous Ova in this model but can be stimulated upon immunization. In contrast, Ova-specific CD8
+ T cells were
suspected to be either unresponsive to Ova challenge or functionally defective. We now extend our investigations on the
mechanisms governing CD8
+ tolerance in SM-Ova mice. We show herein that Ova-specific CD8
+ T cells are not detected
upon challenge with strongly immunogenic Ova vaccines even after depletion of regulatory T cells. Ova-specific CD8
+ T cells
from OT-I mice adoptively transferred to SM-Ova mice started to proliferate in vivo, acquired CD69 and PD-1 but
subsequently down-regulated Bcl-2 and disappeared from the periphery, suggesting a mechanism of peripheral deletion.
Peripheral deletion of endogenous Ova-specific cells was formally demonstrated in chimeric SM-Ova mice engrafted with
bone marrow cells containing T cell precursors from OT-I TCR-transgenic mice. Thus, the present findings demonstrate that
immunological tolerance to muscle autoantigens involves peripheral deletion of autoreactive CD8
+ T cells.
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Introduction
Skeletal muscle is an abundant tissue constituting up to 40% of
the total weight and, consequently, represents the most prominent
source of potential autoantigens in the body. Yet, the precise
mechanisms governing immune tolerance toward muscle antigens
are still poorly understood. In the field of vaccination, muscle is
considered as an immunogenic site and intramuscular injections
have been used to elicit efficient immune priming even with DNA
vaccines. This may be partly related to the intrinsic capacity of
myoblasts and myocytes to act as facultative antigen presenting
cells (APC) during local inflammation [1]. One particular
immunological feature of muscle cells is that they do not express
detectable levels of MHC-I molecules in physiological conditions
while they can up-regulate the expression of both MHC-I and
MHC-II after myoinjury or upon inflammation [2–5]. Local
inflammation drives myoblast conversion into non-professional
APC expressing not only MHC molecules but also some B7-
related co-stimulatory/regulatory molecules. For instance, ICOS-
L, BB-1 and PD-L1 have been detected on muscle cells cultured in
vitro and on muscle fibers of patients with myositis [6–8]. Muscle
cells are also equipped with multiple Toll-like receptors and have
the capacity to secrete chemokines and pro-inflammatory
cytokines such as IL-1a, IL-1b, TNF-a, IL-6, IL-8, IL-15,
RANTES or MCP-1 [8]. Monocytes and others leukocytes are
actively recruited in inflamed muscles where they participate to the
local immune response and contribute to muscle regeneration at
later time points [9]. Hence, the muscle tissue expresses multiple
immunologically relevant molecules that actively support immune
responses directed toward antigens present in muscle.
Despite the apparent immunogenicity of the muscle site,
autoimmune diseases targeting skeletal muscle remain relatively
rare. Indeed, polymyositis, the archetype of autoimmune muscle
disease, has a reported annual incidence ranging, depending on
the diagnostic criteria, between 1 and 8 cases per million [10–12].
This suggests that the muscle tissue may be particularly resistant to
autoimmunity. Polymyositis is characterized histologically by
muscle infiltration of CD8
+ T cells and macrophages, and by
the expression of MHC-I at the surface of myofibers even at
distance from the cellular infiltrate [10–12]. Interestingly,
activated CD8
+ T cells displaying an oligoclonal TCR repertoire
have been detected both in infiltrated muscles as well as in the
circulation of patients with polymyositis, indicating that the
immune attack is antigen-driven and directed against as yet
unidentified autoantigens [13,14]. Even if the pathophysiological
conditions leading to immune activation in polymyositis are still
not fully understood, over-expression of MHC molecules by
muscle fibers and local secretion of pro-inflammatory cytokines
probably contribute to the breakage of immune tolerance against
muscle autoantigens.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36444To study the mechanisms leading to tolerance toward muscle-
expressed autoantigens, we previously generated a transgenic (Tg)
model in which mice express a membrane-bound form of
ovalbumin (Ova) exclusively in the skeletal muscle [15]. In this
model, named SM-Ova, the Ova-transgene has been placed under
the control of a mutated version of the muscle creatine kinase
(MCK) promoter allowing its expression in the skeletal muscle but
not in the myocardium. Immunological analyses of SM-Ova mice
after breeding with Tg mice expressing an MHC-I restricted (OT-
I) or MHC-II restricted (OT-II) Ova-specific TCR revealed an
absence of thymic deletion of Ova-specific clones and an absence
of obvious signs of autoimmunity in unmanipulated mice. In single
Tg SM-Ova mice, Ova-specific CD4
+ T cell dependant responses
as well as anti-Ova IgG antibody production were readily detected
after immunization indicating that CD4
+ T cells are not tolerant
but rather ignorant of muscle-expressed autoantigens [15]. In
striking contrast, specific cytotoxic activities against Ova-pulsed
targets could not be detected after immunization of SM-Ova
suggesting that Ova-specific CD8
+ T cells were either unrespon-
sive to Ova challenge, functionally defective or had been deleted
from the lymphocyte repertoire. Here, we explored this issue and
demonstrate that Ova-reactive CD8
+ T cells are not ignorant nor
blocked in their cytotoxic activity but are rather selectively deleted
from the periphery of SM-Ova mice. Hence, the mechanisms
preventing activation of T cells reactive to muscle-expressed
autoantigens appear to be fundamentally different for CD4
+ T
cells that ignore muscle antigens and for CD8
+ T cells that are
physically deleted from the peripheral repertoire.
Results
Tolerance of the CD8
+ compartment in SM-Ova mice
The capacity of SM-Ova mice to mount a cytotoxic immune
response was reevaluated in vivo using vaccines known to induce
strong CTL responses. For that, B6 or SM-Ova mice were
challenged with Ova-encoding vaccines that consisted of a
defective adeno-associated viral vector rAAV-Ova [16], a
replicative VSV-Ova virus [17] or a live Lm-Ova bacterial strain
[18]. They were then evaluated for their capacity to reject an Ova-
bearing EG7 tumor. While unimmunized B6 mice developed
measurable tumors 5–10 days after EG7 inoculation (not shown),
all B6 mice immunized with Ova-vaccines remained tumor-free
throughout the entire evaluation period (Fig. 1A). This illustrates
the sensitivity of this tumor model to Ova-specific immune
responses as previously shown [19]. In contrast, SM-Ova mice
were unable to reject Ova-expressing EG-7 tumor cells in the same
experimental conditions, indicating that they could not generate
an Ova-specific cytotoxic response in vivo (Fig. 1A). Since we
already reported that SM-Ova mice generate normal Ova-specific
CD4
+ T cell and B cell responses after immunization [15], we
focused our evaluations on the priming of Ova-specific CD8
+ cells.
Mice were immunized with Ova-vaccines and euthanized 7 or 14
days after to assess the percentage of CD8
+ T cells recognizing the
MHC-I restricted immunodominant Ova-derived peptide using
H-2K
b/Ova257–264 pentamer staining. Results showed a signifi-
cant expansion of Ova-specific CD8
+ splenocytes in B6 mice after
immunization with VSV-Ova, Lm-Ova or rAAV-Ova vaccines
(Fig. 1B and C). In striking contrast, SM-Ova mice immunized in
the same condition did not display any detectable Ova-specific
CD8
+ T cell response above the background level (Fig. 1B and C).
This was not due to a global defect in CD8
+ T cells priming since
SM-Ova mice immunized with VSV-Ova displayed a normal
CD8
+ response against the VSV nucleoprotein (Fig. 1B and C).
We even noticed in SM-Ova mice an increase in the frequencies of
CD8
+ cells directed against the VSV nucleoprotein which could
possibly reflect a better immune response to this antigen in the
absence of Ova-specific CD8
+ T response (Fig. 1B and C).
Collectively these data show that SM-Ova mice are selectively
defective in their capacity to mount a CD8
+ T cells response
against Ova-derived antigens. Thus, the absence of cytotoxic
activities in SM-Ova mice after an Ova challenge was not
secondary to a functional defect but was rather due to the absence
Figure 1. Lack of detectable Ova-specific CD8
+ T cell responses
in immunized SM-Ova mice. (A) B6 or SM-Ova mice were
immunized with rAAV-Ova, replicative VSV-Ova or live Lm-Ova. Seven
days after infection with VSV-Ova or Lm-Ova, or 14 days after injection
of rAAV-Ova, mice were inoculated with 1610
6 Ova-bearing EG-7 tumor
cells and monitored during 30–40 days for tumor development. (B)I n
other groups of mice, animals were immunized with the same vaccines
and splenocytes were analyzed 7 or 14 days after by flow cytometry to
evaluate the percentage of CD8
+ T cell recognizing the immunodomi-
nant peptides of Ova or VSV-associated nucleoprotein using H-2K
b/
Ova257–264 or H-2K
b/VSV pentamers staining, respectively. Representa-
tive flow cytometry profiles are shown and numbers indicate
percentage of pentamer-positive cells in the CD8
+-gated population.
Background staining using H-2K
b/VSV pentamers were always below
0.3% of CD8
+ cells as also shown for the staining using H-2K
b/Ova257–264
pentamers (C) Bar graphs represent mean percentages of CD8
+ T cells
positively stained with the indicated H-2K
b/Ova257–264 or H-2K
b/VSV
pentamers in B6 (black bars) or SM-Ova (open bars). Data are
representative of 3 independent experiments, each one performed
with 5–7 mice per group.
doi:10.1371/journal.pone.0036444.g001
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+ T cells or to their incapacity to expand
in vivo.
Tregdo notplaya major inhibitory role on the Ova-specific
CD8
+ T cells response in SM-Ova mice
As regulatory T cells (Treg) naturally exert suppressive functions
on priming and proliferation of autoreactive T cells, we
investigated whether they could be responsible for the inhibition
of Ova-specific CD8
+ T cell responses observed in SM-Ova mice.
For that, mice were treated with the anti-CD25 antibody (PC-61)
using a protocol widely used to deplete Treg in vivo. We have
previously shown that this protocol is sufficient to promote a
spontaneous anti-tumor immune response against Ova-expressing
EG-7 cells [19]. Here, Treg depletion before immunization did
not restore the capacity of SM-Ova mice to mount an Ova-specific
CD8
+ T cell response (Fig. 2A).
However, anti-CD25 antibody treatment may also deplete
activated conventional T cells as for instance endogenous CD8
+ T
cells activated in vivo by Ova-antigen encounter. Therefore, to
further exclude the involvement of Ova-specific Treg, we
adoptively transferred purified naı ¨ve CD8
+ lymphocytes from
SM-Ova mice into lymphopenic CD3
2/2 syngenic recipients
before an Ova challenge. In these experiments, sorted CD4
+
lymphocytes from naı ¨ve B6 mice were co-transferred together with
purified CD8
+ lymphocytes to provide optimal CD4 help. The
results showed that, even in the T cell deficient environment of
CD3
2/2 mice, the CD8
+ T cells purified from SM-Ova mice -
and consequently devoid of CD4
+ Treg from this donor -
remained unable to respond to Ova-immunization (Fig. 2B).
Hence, dominant suppressive mechanisms by CD4
+ T cells from
SM-Ova mice are not primarily involved in the tolerance
mechanisms at study. Instead, this suggested that Ova-specific
CD8
+ precursors from SM-Ova had been deleted from the
peripheral lymphocytic pool of SM-Ova animals.
Deletion of adoptively transferred OT-I cells in SM-Ova mice
To evaluate more directlyhowtheCD8compartment is tolerized
in SM-Ova mice, we adoptively transferred purified Ova-specific
CD8
+ T cells from TCR-Tg OT-I mice harboring the CD45.1
+
allelic variant, and monitored their response to an Ova challenge in
vivo in the environment of SM-Ova mice. Transfer of CD8
+ OT-I T
cells followed 1 day after by immunization with Lm-Ova led to a
comparable level of CD8
+ OT-I cell expansion in B6 and SM-Ova
recipient mice (Fig. 3A). This further confirmed that Ova-specific
CD8
+ immune responses are not persistently inhibited in SM-Ova
mice by a dominant mechanism of suppression.
We next evaluated if naı ¨ve CD8
+ from OT-I mice were
gradually deleted after their transfer to SM-Ova recipients. For
that, purified CD8
+ OT-I T cells were again adoptively transferred
in either B6 or SM-Ova recipients but immunization with Lm-
Ova vaccine was performed only after a lag period of 3 weeks. In
this experimental setting, much fewer CD8
+ OT-I T cells could be
detected in the spleens of SM-Ova mice after immunization as
compared to B6 controls (Fig. 3B). Of note, the few remaining
CD8
+ OT-I T cells detected in the SM-Ova recipient had up-
regulated the immunoregulatory PD-1 receptor on their surface
(Fig. 3B). These data suggested that Ova-reactive CD8
+ T cells are
progressively deleted in the context of the SM-Ova environment.
To formally establish the involvement of peripheral deletion in
tolerance of CD8
+ T cells, we adoptively transferred a high number
of CD8
+ OT-I cells (i.e., 5610
6 cells) and directly monitored their
survival over time in the absence of Ova immunization. For that we
counted the numbers of remaining CD8
+ cells that express the
CD45.1 allelic marker in spleens and LNs. As a result we observed a
significant loss of CD8
+ OT-I T cells over time in unimmunized
SM-Ova mice, with their almost complete disappearance 11 weeks
after transfer (Fig. 4A). This markedly contrasted with the results
observed in B6 recipients in which higher numbers of Ova-specific
CD8
+ T cells persisted overtime. These data unequivocally establish
that Ova-specific CD8
+ T cells are peripherally deleted from the
repertoire of SM-Ova mice.
Autoreactive CD8
+ T cells are exposed to Ova antigens in
the lymph nodes of SM-Ova mice
Several studies previously suggested that peripheral deletion of
self reactive CD8
+ T cells is mediated by dendritic cells migrating
Figure 2. Treg depletion or adoptive cell transfer to CD3
2/2
mice is not sufficient to restore an Ova-specific CD8
+ T cell
response. (A) B6 (n=3) and SM-Ova (n=3) mice were injected i.p. at
day 24 and day 21 with 250 mg of anti-CD25 (PC-61) antibody to
inactivate endogenous Treg, or with PBS, followed by the injection of
rAAV-Ova at day 0. Splenocytes from treated mice were collected 14
days after immunization and analyzed as before by flow cytometry for
t h ep r e s e n c eo fO v a - s p e c i f i cC D 8
+ cells using H-2K
b/Ova257–264
pentamer staining. Representative FACS profiles and bar graphs are
shown and numbers correspond to percentages of cells positively
stained with the H-2K
b/Ova257–264 pentamer in the gated CD8
+
population. (B)2 610
7 purified CD8
+ T cells originating from B6 or
SM-Ova donor mice were adoptively transferred into syngenic CD3
2/2
recipient mice (n=6) together with 3610
7 purified CD4
+ T cells
originating exclusively from B6 donors. Recipient CD3
2/2 mice were
immunized with rAAV-Ova one day later and splenocytes were
collected, enumerated and analyzed 14 days after by flow cytometry
to evaluate the percentages and absolute numbers of Ova-specific
CD8
+ cells. Representative profiles gated on the CD8
+ population are
shown in the left panel and the total numbers of Ova-specific CD8
+ per
spleen are shown in the right bar graph.
doi:10.1371/journal.pone.0036444.g002
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+ T cells are tolerized
in SM-Ova recipient mice. Indicated numbers of purified CD8
+ T cells
from CD45.1
+ OT-I mice were adoptively transferred into B6 or SM-Ova
mice. Recipients were immunized one day later (A) or 3 weeks later (B)
with Lm-Ova and splenocytes were collected, enumerated and analyzed
7 days after immunization by flow cytometry. Bar graphs show the total
numbers of CD8
+CD45.1
+ cells per spleen and the mean percentage of
cells expressing PD-1 in the CD8
+CD45.1
+ gated population. Represen-
tative flow cytometry overlay profiles are shown in (B), illustrating the
intensity of PD-1 staining in the CD8
+CD45.1
+ gated cells recovered
from B6 (black histograms) or SM-Ova mice (open histograms) when 10
5
or 10
4 OT-I cells were adoptively transferred. Negative staining controls
obtained with an isotype-matched irrelevant antibody are also shown
(dashed grey lines). Data are representative of 2 independent
experiments each one performed with 5–8 mice per group.
doi:10.1371/journal.pone.0036444.g003
Figure 4. Adoptively transferred OT-I CD8
+ T cells are deleted
in SM-Ova mice. (A)5 610
6 purified CD8
+CD45.1
+ OT-I cells were
adoptively transferred into SM-Ova or control B6 mice. Recipients were
euthanized 2 days or 11 weeks after to determine the percentages
(indicated in the representative flow cytometry panels on top) and total
numbers (represented below in the bar graphs) of CD8
+CD45.1
+ OT-I
cells recovered from the LNs and spleen of recipient mice. (B)5 610
6
CFSE-labeled CD8
+CD45.1
+ OT-I cells were injected i.v. into SM-Ova or
B6 control mice. Proliferation of gated CD8
+CD45.1
+ cells was evaluated
in the LN and spleen of recipient mice by flow cytometry 7 or 15 days
after their adoptive transfer. Representative profiles are shown and the
indicated numbers correspond to the percentage of gated cells that
have diluted CFSE upon cell division. Data are representative of 2
independent experiments performed with 10 mice per group.
doi:10.1371/journal.pone.0036444.g004
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cross-presented [20,21]. Therefore, we tested whether Ova-
reactive T cells from a non tolerant OT-I donor could respond
to endogenous Ova when transferred to SM-Ova mice. For that,
CFSE-labeled CD8
+ OT-I cells were transferred to SM-Ova mice
in order to evaluate their proliferation in lymphoid organs. Not
surprisingly, a fraction of the OT-I T cells underwent 1 to 6 cycles
of division over a period of 7–15 days post-transfer in SM-Ova
mice while OT-I cells transferred in B6 controls remained mostly
undivided (Fig. 4B). Importantly also, transferred cells appeared to
proliferate earlier and more vigorously in the lymph nodes (i.e.,
which drain muscle) as compared to the spleen (i.e., which does
not drain muscle). These results indicate that OT-I CD8
+ T cells
respond in vivo to their muscle-derived cognate autoantigen in LNs
of SM-Ova mice.
Deletion of peripheral CD8
+ T cells in thymectomized
[SM-Ova6OT-I]F1 mice
We have previously noticed that the number of peripheral
Va2
+CD8
+ T cells in [SM-Ova6OT-I]F1 double Tg mice was
not significantly different from that found in OT-I control mice
[15]. This was previously interpreted as a lack of peripheral
deletion. In light of our present findings, we revisited the possibility
of peripheral deletion in this double Tg model. We reasoned that
cell deletion is presumably compensated in this double Tg model
by the continuous output of high numbers of Ova-specific CD8
+ T
cells from the thymus. This hypothesis would imply that the
number of Va2
+CD8
+ cells in [SM-Ova6OT-I]F1 double Tg
mice should decrease after thymectomy. Indeed, results showed a
significantly faster decrease in the absolute number of
Va2
+Vb5
+CD8
+ T cells over time in the periphery of thymecto-
mized double Tg mice as compared to thymectomized OT-I
controls (Fig. 5A). Interestingly, a higher proportion of
Va2
+Vb5
+CD8
+CD44
highCD62L
high cells were found in double
Tg mice before thymectomy (Fig. 5B). This indicated that a
significant fraction of Ova-specific CD8
+ T cells had been partially
activated by encountering Ova antigen in vivo and are presumably
engaged into a deletional pathway. However, the fate of these
subsets could not be followed after thymectomy since, in both
groups of mice, the majority of CD8
+ cells progressively acquired a
CD44
high phenotype most probably as the result of homeostatic
expansion that compensates for the arrest of thymic production
(data not shown).
Noteworthy, in this TCR-Tg model where large numbers of
OT-I cell are present in the periphery, CD8
+ responses to an Ova
challenge were normal as illustrated by i) the up-regulation of
CD44 on the majority of CD8
+Va2
+ lymphocytes (Fig. 6A), ii) the
prominent in vivo cytotoxic activity against SIINFEKL-pulsed
target cells (Fig. 6B) and iii) the rejection of Ova-bearing tumor
cells even in naı ¨ve [SM-Ova6OT-I]F1 mice (Fig. 6C). All together
these results demonstrate that the CD8
+ compartment respond
normally to an Ova challenge in the double Tg [SM-Ova6OT-
I]F1 mice and that the peripheral deletion is not able to tolerize
the CD8
+ compartment in this repertoire-biased model where
virtually all CD8
+ cells are directed against Ova.
Peripheral deletion of endogenously produced Ova-
specific CD8
+ T cells in SM-Ova
Our results so far have demonstrated that adoptively-transferred
exogenous Ova-reactive T cells are progressively deleted in the
periphery of SM-Ova mice and therefore indirectly suggest that
endogenously produced Ova-specific CD8
+ are also tolerized by a
mechanism of peripheral deletion. To definitively establish this
point, we turned to bone marrow chimera experiments as they
represent the best model to directly study the fate of endogenously-
produced Ova-specific CD8
+ T cells in the context of a polyclonal
repertoire and also offer the possibility to examine their
differentiation in the thymus. For this, lethally-irradiated SM-
Ova mice were reconstituted with a 9:1 mixture of bone marrow
cells from B6 and CD45.1
+ OT-I mice, respectively. After
reconstitution in SM-Ova mice, the fate of emerging CD45.1
+
cells was monitored over time from blood samples, and then
analyzed in central and peripheral organs after sacrificing the
mice. Results demonstrated that the frequency of CD8
+CD45.1
+
Figure 5. Peripheral deletion of Ova-specific CD8
+ can be evidenced in double transgenic [OT-I6SM-Ova]F1 mice after thymectomy.
(A) Double transgenic [OT-I6SM-Ova]F1 and control OT-I mice were thymectomized at day 0. The total numbers of Va2
+Vb5
+CD8
+ cells were
determined from blood samples one day before thymectomy and 60 or 90 days after thymectomy. (B) Representative flow cytometry overlay profile
illustrating the level of CD44 expression in peripheral blood cells from unmanipulated [OT-I6SM-Ova]F1 or OT-I control mice in the gated
Va2
+Vb5
+CD8
+ population. (C) Representative flow cytometry profiles and a scatter plot graph illustrating the percentage of CD44
highCD62L
high cells
found in blood samples from unmanipulated [OT-I6SM-Ova]F1 or OT-I control mice in the gated Va2
+Vb5
+CD8
+ population. Data are representative
of 2 independent experiments with 8–9 mice per group.
doi:10.1371/journal.pone.0036444.g005
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weeks after reconstitution gradually decreased as compared to B6
recipients (Fig. 7A, right panel). In contrast, CD4
+CD45.1
+ T
lymphocytes and CD19
+CD45.1
+ B lymphocytes remained in
similar frequencies in B6 and SM-Ova mice (Fig. 7A, left panel).
Ten weeks after reconstitution, the absolute numbers of Ova-
specific CD8
+CD45.1
+ T cells were reduced by 75 to 94% in the
LNs, spleen and blood of SM-Ova chimeric mice, demonstrating
their peripheral deletion (Fig. 7B). The situation was different in
the thymus where CD8
+CD45.1
+ T cells were found in similar
numbers in SM-Ova as compared to B6 recipient mice (Fig. 7B,
right panel), indicating that deletion of Ova-specific CD8
+ T cells
was only peripheral but not central.
Phenotypic analysis of the remaining peripheral CD8
+CD45.1
+
cells further evidenced a marked increase in the percentage of cells
expressing the early activation marker CD69 and the immuno-
regulatory protein PD-1 in the LNs of SM-Ova mice as compared
to B6 mice (Fig. 7C). This was not the case for cells harvested from
the spleens of SM-Ova mice, indicating that Ova-specific CD8
+ T
cells encounter their cognate antigen in the muscle-draining LNs
rather than in the spleen. CD8
+CD45.1
+ cells expressing
CD44
high, a late marker of cell activation, were instead found at
higher frequencies in the spleens and in the circulation of SM-Ova
mice (Fig. 7D, right panel), suggesting that these T cells rapidly
recirculate after having encountered their auto-antigen and
preferentially relocalize to the spleen. Apart from the phenotypic
changes, CD8
+CD45.1
+ T cells also proliferate more intensely in
SM-Ova mice, as evidenced by the higher frequency of cells
expressing the nuclear protein Ki-67 characteristic of cell division
(Fig. 7D, left panel). Finally, CD8
+CD45.1
+ T cells remaining in
SM-Ova mice were found to express significantly lower levels of
the anti-apoptotic protein Bcl-2, suggesting that their probability
of survival was indeed hindered in the presence of their muscle-
expressed cognate autoantigen in vivo (Fig. 7E).
Discussion
Muscle represents a major constituent of the body, yet the
precise mechanisms governing immune priming/tolerance toward
muscle antigens are still poorly defined. In this study, we examined
how immunological tolerance is established in the CD8
+ T cell
compartment of SM-Ova Tg mice that express an Ova neo-
autoantigen specifically in skeletal muscle. We previously demon-
strated that CD4
+ T cell as well as B cell responses can be readily
induced in SM-Ova single Tg mice after immunization with Ova,
indicating that immunological ignorance of muscle-derived
autoantigens rather than tolerance prevails in the steady state for
these lymphocyte subsets [15]. In contrast, Ova-specific CD8
+ T
cells responses were not detected suggesting that a different
mechanism of tolerance controls the emergence of muscle
autoreactive CTLs. Since the number of CD8
+ T cells was found
to be normal in the double Tg [OT-I6SM-Ova]F1 mice, Ova-
specific CD8
+ T cells defect in SM-Ova models was interpreted as
being possibly associated with a functional defect. We demonstrate
herein that muscle-reactive CD8
+ T cells are in fact deleted from
the peripheral T cell repertoire of single transgenic SM-Ova mice,
a phenomenon that is not apparent in the double Tg [OT-I6SM-
Ova]F1 mice.
Several observations in this report demonstrate that peripheral
deletion is the central mechanism of CD8
+ T cell tolerance in SM-
Ova mice: i) the absence of detectable CD8
+ lymphocytes specific
for H-2K
b/Ova257–264, even upon challenge with strongly
immunogenic rAAV-Ova, Lm-Ova or VSV-Ova vaccines
(Fig. 1), ii) the gradual loss of exogenous CD8
+ T cells from
OT-I mice adoptively transferred to SM-Ova (Fig. 3 and 4), and
iii) the peripheral loss overtime of endogenously-produced Ova-
specific CD8
+ T cells in chimeric SM-Ova mice engrafted with
bone marrow cells partly derived from OT-I mice (Fig. 7).
Noteworthy, in the latter SM-Ova chimeric mice, the loss of Ova-
specific CD8
+ T cells could only be detected in the peripheral
lymphoid compartments but not in the thymus, confirming the
absence of central deletion (Fig. 7B, right panel) which is consistent
with the absence of Ova-transgene expression in the thymus of
SM-Ova mice [15].
Peripheral deletion of autoreactive CD8
+ T cells was not
evidenced in double Tg [OT-I6SM-Ova]F1 mice as compared to
single Tg OT-I control mice (Fig. 5A, day 21). This observation
confirms that peripheral deletion in this context is masked at least
Figure 6. CD8
+ cells from [SM-Ova6OT-I]F1 double Tg mice are not functionally defective. (A) Double Tg [SM-Ova6OT-I]F1 mice (n=3)
and control OT-I mice (n=3) were either left unmanipulated or immunized i.v. with an Ova-encoding lentiviral vector as described [37].
Representative flow cytometry overlay profiles illustrate the level of CD44 or Ki-67 in the gated CD8
+Va2
+ T cells population collected from the
spleens of OT-I (blue histograms) or [SM-Ova6OT-I]F1 (red dashed histograms) mice 7 days later. (B) Naive double transgenic [SM-Ova6OT-I]F1
(n=8), OT-I mice (n=8) and naive control B6 mice (n=2) were injected i.v with a 1:1 mixture of CFSE
high unpulsed cells and CFSE
low SIINFEKL pulsed
cells as described [15]. Spleens were harvested 5 hours later and analyzed for detection of CFSE-labeled cells. In vivo specific cytotoxic activities were
determined by calculating the percentage of specific lysis, as described [15]. (C) Naive [SM-Ova6OT-I]F1 (n=5), control OT-I mice (n=5) mice and
naive B6 mice (n=6) were inoculated with 3610
6 Ova-bearing EG-7 tumor cells and monitored during 30–40 days for tumor development, as
described [19].
doi:10.1371/journal.pone.0036444.g006
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T cells. This view is further supported by the observation that
autoreactive CD8
+Va2
+Vb5
+ lymphocytes decline more rapidly
overtime in thymectomized [OT-I6SM-Ova]F1 mice than in
thymectomized OT-I control mice (Fig. 5A). This underscores that
TCR/antigen double Tg mice do not represent appropriate
models to study peripheral deletion. Instead, as used here,
chimeric mice reconstituted with a mixture of bone marrow cells
composed by 90% of cells originating from control mice and by
only 10% of cells from the TCR-Tg mice (i.e., OT-I mice) allowed
to more closely model the situation where endogenously produced
lymphocytes specific for a given antigen represent only a minority
of the T cell repertoire. In these chimeric mice, peripheral deletion
of Ova-specific CD8
+ cells is readily demonstrable (Fig. 7),
probably because deleted cells are progressively replaced by
polyclonal non-Tg TCR lymphocytes that may display a better
fitness in situation of interclonal competition [22,23].
From the present data, it is possible to approximate the rate at
which peripheral deletion affects autoreactive CD8
+ T cells.
Around 1610
3 Ova-specific CD8
+ cells could be detected in LNs
of SM-Ova mice 11 weeks post-transfer, as compared to
approximately 3610
4 cells in control mice (Fig. 4A, left panel).
Therefore, a little bit less than 3610
3 cells are deleted per week.
This is consistent with the fact that transfer of less than 1610
4 cells
resulted in a complete deletion of transferred cells 3 weeks later, as
attested by our inability to detect their expansion upon Lm-Ova
challenge (data not shown, similar to experiments presented in
Fig. 3). This may further explain our inability to evidence the
peripheral deletion in [OT-I6SM-Ova]F1 double transgenic mice
as thymic output has been estimated to range between 10
4–10
6
cells per day depending on age [24]. Noteworthy, this rate of
peripheral deletion is still largely sufficient for the complete
attrition of all Ova-specific CD8
+ cells in single Tg SM-Ova mice,
since the total number of CD8
+ cells directed against a given
antigenic epitope in naive mice has been estimated to be around
200 cells [25].
As we used H-2K
b/Ova257–264 pentamer staining to detect
Ova-specific CD8
+ cells directed against the immunodominant
SIINFEKL peptide and the high affinity OT-I cells in our
adoptive transfer experiments, the question may arise as whether
lower affinity Ova-specific CD8
+ T cells are possibly preserved or
Figure 7. Peripheral deletion of endogenously produced Ova-
specific CD8
+ T cells in chimeric SM-Ova mice. B6 (n=8) and SM-
Ova (n=13) recipient mice were lethally irradiated and reconstituted
one day after with bone marrow cells collected from B6 donor mice
mixed with 10% bone marrow cells collected from CD45.1
+ OT-I donor
mice. (A) Left bar graph illustrates the percentages of cells in the CD4
+,
CD19
+ or CD8
+ gated populations expressing the CD45.1 marker in
blood samples from B6 (black bars) or SM-Ova (open bars) recipient
mice 6 weeks after bone marrow transplantation. Right bar graph
illustrates the percentage of CD8
+ PBL expressing the CD45.1 marker 6,
8 or 10 weeks after bone marrow transplantation. (B) Absolute numbers
of CD8
+ CD45.1
+ OT-I T cells found in LN, spleen, blood and thymus of
chimeric mice were enumerated and analyzed by flow cytometry 10
weeks after bone marrow engraftment. (C, D) Bar graphs show the
percentages of cells expressing CD69, PD-1, CD44 or Ki-67 marker in the
gated CD8
+CD45.1
+ population. (E) Representative flow cytometry
overlay profiles illustrate the level of Bcl-2 expression in the gated
CD8
+CD45.1
+ T cells population collected from the LN and spleen of B6
(dark histograms) or SM-Ova (open histograms) recipient mice 10 weeks
after bone marrow transplantation. Isotype-matched negative staining
controls are also shown (dashed grey lines). The corresponding bar
graph illustrating the mean fluorescence intensities (MFI) of Bcl-2
expression is shown in the right panel.
doi:10.1371/journal.pone.0036444.g007
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mice immunized with strongly immunogenic vaccines encoding
the entire Ova protein were unable to reject an Ova-bearing
tumor (Fig. 1A) suggests that lower affinity Ova-specific CD8
+ T
cells are either also absent or unable to mediate an efficient
cytotoxic immune response against Ova-expressing cells.
Another important question concerns the location where Ova-
derived antigens are presented to autoreactive CD8
+ T cells. From
the results of CFSE-labeled OT-I T cell transfer experiments, it is
likely that antigen encounter occurs in the LNs rather than in the
spleen (Fig. 4B). In agreement, we also found in the chimeric
model that OT-I derived CD8
+ T cells upregulated the early
activation markers CD69 and PD-1 in the LNs but not in the
spleen (Fig. 7C).Yet, we observed a higher fraction of cells
displaying the late activation marker CD44
high in the spleen as
compared to the LNs (Fig. 7D). Since CD44
high lymphocytes home
more efficiently to the spleen than to the LNs [26], these data are
compatible with a sequence of events where Ova-specific CD8
+ T
cells first encounter their cognate autoantigen in the LNs draining
muscle territories, rapidly upregulate CD69 and PD-1, proliferate,
acquire the CD44
high marker, relocalize preferentially to the
spleen and finally die after having down-regulated the anti-
apoptotic factor Bcl-2 (Fig. 4 and 7). Induction of cell death in this
situation most probably involves partial T cell activation in
absence of costimulatory molecules at the surface of APCs and
paucity of cytokine secretion in non inflammatory conditions
[21,27–29]. Recent work has shown that not only lack of accessory
molecules but also presence of inhibitory signals can promote
tolerization [30]. One such signal could be delivered to PD-1-
expressing lymphocytes by PD-L1 or PD-L2 ligands expressed by
APCs. Indeed, numerous studies have now recognized the PD-1
pathway as an essential molecular trigger involved in the
maintenance of tolerance to tissue antigens [30,31]. Here, PD-1
is expressed by a significant fraction of Ova-specific CD8
+ T cells
of SM-Ova mice (Fig. 3B, 4C and 7C). Therefore, it is conceivable
that PD-1 participates in induction of tolerance and possibly in
induction of cell death. Such a view would be in agreement with
the finding that PD-1 upregulation has been recently found to
represent one of the key molecular signature of CD8
+ T cells
undergoing deletional tolerance, together with the downregulation
of Bcl-2 and IL-7a expression [32]. In line with this, we recently
reported that that PD-L1 gene transfer protects muscle from CD8
+
cytotoxicity in gene therapy settings [16].
A puzzling feature in the SM-Ova model is the inability to
induce myositis upon transfer of OT-I cells and immunization,
even if the transferred cells can reject Ova-bearing tumors (data
not shown). To our knowledge, in all other transgenic models
where Ova is expressed in tissues such as pancreas, intestine, skin
or prostate, the adoptive transfer of OT-I T cells, either activated
in vitro or in vivo by immunization with VSV-Ova or Lm-Ova live
vectors, has led to cell infiltration and autoimmunty directed
against the Ova-expressing tissue [17,33–35]. Therefore, other
muscle-specific mechanisms may be at play to control T cell-
mediated cytotoxicity against this tissue. Noteworthy, muscle fibers
do not physiologically express MHC-I molecules and are therefore
intrinsically resistant to CD8
+ T cells autoimmune aggression [2–
5]. In human polymyositis, MHC-I is upregulated at the surface of
myofibers and the presence of MHC-I-expressing myofibers
surrounded by CD8
+ lymphocytes is one of the hallmarks and
diagnosis criteria of polymyositis [10–12]. Future experimental
studies should address whether induction of stable MHC-I
expression in muscle by gene transfer could lead to the breakage
of tolerance in this model.
In summary, we show herein that tolerance toward an
autoantigen expressed in skeletal muscles involves the deletion of
high affinity autoreactive CD8
+ T cells from the peripheral
repertoire, a mechanism that prevents the generation of CTLs
upon immune challenge with the same antigen. These results shed
light on the mechanisms governing immune tolerance toward
muscle antigens and could be of importance to better understand
the pathogenesis of muscle autoimmune diseases.
Materials and Methods
Mice
Transgenic SM-Ova mice, expressing a membrane-bound form
of ovalubumin (Ova) exclusively in skeletal muscle have been
described previously [15]. In some experiments, SM-Ova mice
were crossed for one generation with TCR-Tg OT-I mice
harboring large numbers of CD8
+ T cells that specifically
recognize the Ova257–264 peptide in the context of MHC-I (H-
2K
b) presentation. OT-I, C57BL/6 (B6) and congenic B6 mice
harboring the CD45.1 allelic marker were obtained from Charles
River Laboratories. CD3e
2/2 mice were obtained from ‘‘Centre
de De ´veloppement des Techniques Avance ´es’’ (CDTA, Orle ´ans,
France). Mice were housed in a specific pathogen-free barrier
facility and were analyzed between 8–16 weeks of age. Animal
experiments were approved by the local institutional ethic
committee for animal experimentation (authorization #0211-22
‘‘Comite ´R e ´gional d’E ´thique en Expe ´rimentation Animale de
Normandie’’).
Reagents, antibodies, flow cytometry and Treg depletion
Fluorochrome-conjugated antibodies to mouse CD4, CD8,
CD45.1, CD44, CD62L, PD-1, CD69 and unlabeled CD16/
CD32 antibodies were obtained from eBioscience. Fluorescently
labeled anti- Va2, Vb5, Ki-67 and Bcl-2 were purchased from BD
Biosciences. Intracellular Ki-67 and Bcl-2 staining were performed
according to the manufacturer’s protocol. PE-conjugated H-2K
b/
Ova257–264 or H2-K
b/VSV pentamers were used to detect CD8
+
cells that specifically recognize the immunodominant SIINFEKL
peptide from Ova or the RGYVYQGL peptide from VSV-
nucleoprotein using the manufacturer’s protocol (ProImmune).
Flow cytometry measurements of single-cell suspensions derived
from spleen, peripheral blood (PBL), thymus or pooled lymph
nodes (LNs) (i.e., maxillary, axillary, brachial, inguinal, para-aortic
and popliteal lymph nodes) were performed using standard
procedures on a FACSCanto (BD Biosciences) and analyses were
made using the FlowJo software (Tree Star). In some experiments,
the monoclonal antibody PC-61 directed against CD25 was used
to inactivate CD4
+CD25
+ Treg in vivo. For that, 250 mg of purified
antibody (BioXcell) were injected i.p. at day 24 and at day 21a s
described previously [19].
Mice immunization
Replicative vesicular stomatitis virus (VSV) encoding Ova
(VSV-Ova) [17] and a live strain of Listeria monocytogenes expressing
Ova (Lm-Ova) [18] were kindly provided by L. Lefranc ¸ois and G.
Lauvau, respectively. Where indicated, B6 or SM-Ova mice were
injected i.v. with 1610
6 pfu VSV-Ova or Lm-Ova preparations
diluted in 100 ml of PBS. Immune responses were evaluated 7 days
after infection. The plasmid construct for the preparation of
recombinant adeno-associated virus encoding for soluble Ova
(rAAV-Ova) [36] was kindly provided by R. Herzog. Where
indicated, anesthetized B6 or SM-Ova mice were injected i.m.
with 1610
11 equivalent vector genomes of rAAV2/1-Ova
preparations diluted in 50 ml of PBS and analyzed 14 days after.
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Ova-specific CD8
+T cells were obtained from the LNs of CD45.1
+
TCR-Tg OT-I mice and purified by magnetic sorting using a CD8
+
negative isolation kit (Invitrogen). Between 92 and 96% of the purified
cells displayed a CD8
+Va2
+CD45.1
+CD4
2CD19
2 phenotype as
assessed by flow cytometry. Indicated numbers of purified OT-I T
cells were then adoptively transferred into SM-Ova or B6 recipients
by i.v. injection and, where indicated, recipient mice were infected 1
day or 3 weeks later by Lm-Ova. For in vivo proliferation assays,
purified 5610
6 CD45.1
+ O T - ITc e l l sw e r es t a i n e dw i t h5mMC F S E
(Invitrogen) for 10 min at 37uC ,w a s h e da n di n j e c t e di . v .i n t oS M -
Ova or B6 recipient mice. For adoptive T cell transfer into CD3
2/2
recipient mice, 2610
7 CD8
+ T cells derived from the LNs and spleen
of either SM-Ova or B6 donor mice were purified using magnetic
sorting and then injected i.v. into CD3
2/2 recipient mice together
with 3610
7 magnetically purified CD4
+ helper T cells derived
exclusively from B6 donors.
Tumor model
B6 or SM-Ova mice, immunized 7 days before with VSV-Ova
or Lm-Ova, or 14 days before with rAAV-Ova, were injected s.c.
in their shaved flanks with 1610
6 EL4-Ova (EG-7) tumor cells
obtained from subconfluent in vitro cultures. Mice were then
examined every third day and tumor development was monitored
for 30–40 days as described [19].
Bone-marrow chimeras
Bone marrow transplantation was performed on B6 or SM-Ova
mice at 8 weeks of age. For that, B6 or SM-Ova mice were lethally
irradiated on day 0 by administration of 2 cumulative doses of
5 Gy each separated by a 3 hours rest period using a Faxitron
CP225 X-ray cabinet set at 220 kV and 10 mA. Irradiated
recipients were reconstituted one day after by i.v. injection of
9610
6 bone marrow cells collected from B6 mice mixed with
1610
6 bone marrow cells from CD45.1
+ OT-I mice.
Data representation and statistical analysis
All data are shown as mean values and error bars represent
SEM. Parametric tests were used for statistical comparison
between experimental groups using one-way analysis of variance
(ANOVA). Differences were considered statistically significant
when p values were less than 0.05(*), 0.01 (**) or 0.001 (***). All
calculations were performed using the Prism software (GraphPad).
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